Drug Type Small molecule drug |
Synonyms ULECACICLIB |
Target |
Action inhibitors |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H33FN8S |
InChIKeyPOFVJRKJJBFPII-UHFFFAOYSA-N |
CAS Registry2075750-05-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 2 | Australia | 16 Jun 2021 | |
Brain Cancer | Phase 2 | Australia | - | |
Pancreatic Cancer | Preclinical | Australia | 10 Nov 2021 |